Editorial: Innovative Radiopharmaceuticals in Oncology and Neurology
نویسندگان
چکیده
منابع مشابه
Editorial: Innovative Radiopharmaceuticals in Oncology and Neurology
1 Centre Régional de Recherche en Cancérologie Nantes/Angers (CRCNA), UMR892 Inserm, Nantes, France, 2 6299 CNRS, Nantes, France, 3 Université de Nantes, Nantes, France, 4 GIP Arronax, Saint-Herblain, France, 5 UMR Inserm U930, Tours, France, 6 Université François Rabelais, Tours, France, 7 CHRU de Tours, Hôpital Bretonneau, Tours, France, 8 Service de Médecine Nucléaire, Institut de Cancérolog...
متن کاملEditorial: Charged Particles in Oncology
High-energy charged particles represent a cutting-edge technique in radiation oncology (1). Protons and carbon ions are used in several centers all over the world for the treatment of different solid tumors. Typical indications are ocular malignancies, tumors of the base of the skull, hepatocellular carcinomas, and various sarcomas (2). The physical characteristics of the charged particles (Bra...
متن کاملPediatric Neurology Editorial Touch MEdical MEdia
Touch MEdical MEdia 1 It is no small task to choose from among the many accomplishments and advances in child neurology that epitomize the year’s achievements. Making choices means making inclusions and omissions others would not have made. Choices notwithstanding, the small sampling presented at the 2015 American Academy of Neurology meeting in Washington, DC, US, serves to reflect the breadth...
متن کاملEditorial: Non-invasive Brain Stimulation in Neurology and Psychiatry
In recent years, greater attention has been paid to alternative treatments in neurology and psychiatry, with the main aim of restoring or “normalizing” function in aberrant brain circuits, in order to have a positive impact on the patient’s quality of life. Non-invasive brain stimulation (NIBS) methods such as transcranial magnetic stimulation (TMS) or transcranial direct current stimulation (t...
متن کاملAccess to innovative oncology medicines in Europe
This article intends to give an overview about developments in European Regulatory and Health Technology Assessment (HTA) of new cancer drugs. As background information, it will refer to an overview article by Bergmann et al. [1], which pointed out the status and the limitations of the current system. The authors discussed possible steps to improve the interface between regulators and HTA bodie...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Medicine
سال: 2017
ISSN: 2296-858X
DOI: 10.3389/fmed.2016.00074